pulseData

AI-driven analytics for kidney disease management

New York City, New York, United States

About pulseData

pulseData focuses on improving the management of Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD) through the use of artificial intelligence and machine learning. The company provides healthcare providers with advanced data analytics tools that help identify high-risk patients, predict renal failure events, and track patient care. This enables healthcare providers to offer value-based care, which emphasizes high-quality treatment while keeping costs low. pulseData partners with healthcare institutions on a subscription basis, granting them access to its AI-driven platform that aids in identifying undiagnosed patients and optimizing care workflows. The goal of pulseData is to enhance patient outcomes and reduce unexpected medical expenses for both patients and providers.

New York City, New YorkHeadquarters
2015Year Founded
$19.2MTotal Funding
SERIES_ACompany Stage
Data & Analytics, AI & Machine Learning, HealthcareIndustries
11-50Employees

Risks

Emerging AI healthcare startups threaten pulseData's market share in kidney care.
Potential inaccuracies in algorithms could misidentify high-risk patients, affecting outcomes.
Data privacy concerns may undermine client confidence and lead to penalties.

Differentiation

pulseData specializes in AI-driven kidney care, focusing on CKD and ESRD.
The company offers predictive analytics to identify high-risk patients and optimize care.
pulseData partners with healthcare providers to deliver value-based, cost-effective care.

Upsides

Increased telehealth adoption enhances AI model accuracy for chronic disease prediction.
AI integration in EHR systems improves data flow and patient monitoring.
Rise of personalized medicine boosts demand for predictive analytics tools.

Funding

Total raised$19.16 M
Latest valuation$82.50 M
StageSERIES_A